Could the future of healthcare be intertwined with cannabis-based medicines?

A recent report by Prohibition Partners, a data, media and tech company operating in the cannabis industry, reveals a remarkable 650% surge in clinical trials using cannabis-based medicines to alleviate symptoms associated with conditions such as cancer, epilepsy and autism spectrum disorder since 2010.

Stephen Murphy, CEO of Prohibition Partners, noted that this recommendation could bridge the gap between medical and adult-use cannabis, further advancing patient access and pharmaceutical industry involvement in meeting patient demand.

Biden Administration's Cannabis Recommendation: Implications for Access and Industry

The report highlights the potential for cannabinoid-based treatments in various medical fields. The findings come as the Department of Health and Human Services (HHS) recommended reclassifying …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.